Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 38Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 28Myelodysplastic Syndromes 21Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 18Pancreatic Neoplasms 17Triple Negative Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Ovarian Neoplasms 14Glioblastoma 14Carcinoma, Renal Cell 14Squamous Cell Carcinoma of Head and Neck 13Burkitt Lymphoma 13Urinary Bladder Neoplasms 10Mouth Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma 10Oropharyngeal Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Laryngeal Neoplasms 9Brain Neoplasms 9

Interventions

atezolizumab 2lipoarabinomannan 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Lamivudine 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Lung Small Cell Carcinoma × Specimen Handling × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡